Premium
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection
Author(s) -
KOLKMAN J. J.,
TAN T. G.,
POOL M. OUDKERK,
KLEEF W. A. VAN,
GERAEDTS A. A. M.,
TIMMERMAN R. J.,
CROBACH L. F. S. J.,
NICOLAI J. J.,
WOLFF A. A. C.,
LAAN J. VAN DER
Publication year - 1997
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1997.00254.x
Subject(s) - rapid urease test , omeprazole , medicine , clarithromycin , gastroenterology , helicobacter pylori , ranitidine , amoxicillin , ranitidine hydrochloride , gastritis , antibacterial agent , spirillaceae , antibiotics , microbiology and biotechnology , biology
Aim: To compare the efficacy of ranitidine bismuth citrate plus clarithromycin (RBC–C) vs. omeprazole plus amoxycillin (OME–AMO) in the cure of Helicobacter pylori infection. Methods: In this double‐blind, multicentre, parallel‐group study 122 H. pylori ‐positive patients with active duodenal ulcer or gastritis, with confirmed history of duodenal ulcer, were randomized to treatment with ranitidine bismuth citrate 400 mg b.d. plus clarithromycin 500 mg b.d. or omeprazole 20 mg b.d. plus amoxycillin 1000 mg b.d. for 14 days, followed by 14 days of ranitidine bismuth citrate 400 mg b.d. or omeprazole 20 mg once daily, respectively, to facilitate ulcer healing. Endoscopy was carried out at the start of the study and 28 days after the end of treatment. At each endoscopy four biopsies were obtained from the antrum and four biopsies from the corpus, for rapid urease test, histology and culture. H. pylori infection was defined as a positive urease test, confirmed by histology or culture. Cure of H. pylori infection was defined as negative urease test, histology or culture from both sites. Results: Per‐protocol, all‐patients‐treated and intention‐to‐treat cure rates (95% confidence interval) were, respectively, 90% (81–89%), 90% (82–89%) and 84% (74–93%) for ranitidine bismuth citrate plus clarithromycin, and 39% (27–54%), 44% (31–57%) and 41% (29–53%) for omeprazole plus amoxycillin, P < 0.00001. Both regimens were well tolerated. Eight patients were lost to follow‐up, for lack of efficacy (one patient), adverse events (three patients) or refusal of second endoscopy (four patients). Conclusion: Ranitidine bismuth citrate 400 mg b.d. with clarithromycin 500 mg b.d. is superior to omeprazole 20 mg b.d. with amoxycillin 1000 mg b.d. Ranitidine bismuth citrate with clarithromycin is the first dual therapy with high cure rates and good tolerance, and is easy to take. It may therefore prove a suitable first‐line treatment in H. pylori infection.